PL355331A1 - Nowa kompozycja i zastosowanie - Google Patents

Nowa kompozycja i zastosowanie

Info

Publication number
PL355331A1
PL355331A1 PL00355331A PL35533100A PL355331A1 PL 355331 A1 PL355331 A1 PL 355331A1 PL 00355331 A PL00355331 A PL 00355331A PL 35533100 A PL35533100 A PL 35533100A PL 355331 A1 PL355331 A1 PL 355331A1
Authority
PL
Poland
Prior art keywords
novel composition
thiazolidinedione
pharmaceutically acceptable
acceptable carrier
pharmaceutical composition
Prior art date
Application number
PL00355331A
Other languages
English (en)
Other versions
PL200943B1 (pl
Inventor
Karen Lewis
Nicola Jayne Lilliott
Donald Colin Mackenzie
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27447849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL355331(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9927119.9A external-priority patent/GB9927119D0/en
Priority claimed from GBGB9927120.7A external-priority patent/GB9927120D0/en
Priority claimed from GB0013240A external-priority patent/GB0013240D0/en
Priority claimed from GB0013236A external-priority patent/GB0013236D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of PL355331A1 publication Critical patent/PL355331A1/pl
Publication of PL200943B1 publication Critical patent/PL200943B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL355331A 1999-11-16 2000-11-16 Kompozycja farmaceutyczna zawierająca kombinację substancji aktywnych - tiazolidynodionu i chlorowodorku metforminy i sposób jej wytwarzania PL200943B1 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9927119.9A GB9927119D0 (en) 1999-11-16 1999-11-16 Novel composition and use
GBGB9927120.7A GB9927120D0 (en) 1999-11-16 1999-11-16 Novel composition and use
GB0013240A GB0013240D0 (en) 2000-05-31 2000-05-31 Novel composition and use
GB0013236A GB0013236D0 (en) 2000-05-31 2000-05-31 Novel composition and use
PCT/GB2000/004368 WO2001035941A2 (en) 1999-11-16 2000-11-16 Novel composition based on a thiazolidinedione and metformin and use

Publications (2)

Publication Number Publication Date
PL355331A1 true PL355331A1 (pl) 2004-04-19
PL200943B1 PL200943B1 (pl) 2009-02-27

Family

ID=27447849

Family Applications (1)

Application Number Title Priority Date Filing Date
PL355331A PL200943B1 (pl) 1999-11-16 2000-11-16 Kompozycja farmaceutyczna zawierająca kombinację substancji aktywnych - tiazolidynodionu i chlorowodorku metforminy i sposób jej wytwarzania

Country Status (40)

Country Link
US (1) US8236345B2 (pl)
EP (3) EP1231918B1 (pl)
JP (2) JP4865975B2 (pl)
KR (1) KR100760063B1 (pl)
CN (1) CN1222290C (pl)
AP (1) AP1389A (pl)
AR (2) AR030920A1 (pl)
AT (1) ATE292466T1 (pl)
AU (3) AU775654B2 (pl)
BG (1) BG65616B1 (pl)
BR (1) BR0015605A (pl)
CA (1) CA2388846A1 (pl)
CO (1) CO5300392A1 (pl)
CZ (1) CZ302500B6 (pl)
DE (1) DE60019329T2 (pl)
DK (1) DK1231918T3 (pl)
DZ (1) DZ3251A1 (pl)
EA (1) EA004878B1 (pl)
ES (1) ES2240199T3 (pl)
HK (1) HK1049788B (pl)
HR (1) HRP20020416B1 (pl)
HU (1) HU229960B1 (pl)
IL (3) IL149618A0 (pl)
MA (1) MA25567A1 (pl)
ME (1) ME00318B (pl)
MX (1) MXPA02005005A (pl)
MY (1) MY125516A (pl)
NO (1) NO329926B1 (pl)
NZ (1) NZ518946A (pl)
OA (1) OA12513A (pl)
PE (1) PE20011011A1 (pl)
PL (1) PL200943B1 (pl)
PT (1) PT1231918E (pl)
RS (1) RS51343B (pl)
SI (1) SI1231918T1 (pl)
SK (1) SK286985B6 (pl)
TW (1) TWI240626B (pl)
UA (1) UA73150C2 (pl)
UY (1) UY26439A1 (pl)
WO (1) WO2001035941A2 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001257456B2 (en) * 2000-05-01 2006-02-09 Aeropharm Technology, Inc. A core formulation
CA2453782A1 (en) * 2001-07-10 2003-01-23 Kos Life Sciences, Inc. Core formulation comprising troglitazone and a biguanide
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
EP1515701B1 (en) * 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
CN100367960C (zh) * 2002-07-11 2008-02-13 武田药品工业株式会社 包衣制剂的制备方法
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP4694841B2 (ja) * 2002-09-20 2011-06-08 アンドルックス ラボズ リミテッド ライアビリティ カンパニー ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
PL377403A1 (pl) 2003-01-29 2006-02-06 Takeda Pharmaceutical Company Limited Sposób wytwarzania preparatu powlekanego
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
JP4739189B2 (ja) * 2004-04-14 2011-08-03 武田薬品工業株式会社 固形製剤
EP1772149A1 (en) * 2004-07-27 2007-04-11 Kowa Company. Ltd. Drug for prevention or treatment of diabetes
PT1878426E (pt) * 2005-04-26 2010-06-28 Dainippon Sumitomo Pharma Co Preparação granulada contendo um composto de biguanida
TWI384985B (zh) * 2005-12-22 2013-02-11 Takeda Pharmaceutical 固體製劑
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
JP4893750B2 (ja) 2006-12-26 2012-03-07 富士通株式会社 データ圧縮装置およびデータ復元装置
PL2107905T3 (pl) 2007-02-01 2011-04-29 Takeda Pharmaceuticals Co Stały preparat zawierający alogliptynę i pioglitazon
WO2008095263A1 (en) 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
TR200803177A2 (tr) * 2008-05-06 2009-11-23 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
PE20151924A1 (es) 2008-08-12 2016-01-13 Zinfandel Pharmaceuticals Inc Metodo de identificacion de factores de riesgo de la enfermedad
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
FR2951945B1 (fr) * 2009-11-05 2013-08-09 Sanofi Aventis Composition pharmaceutique
RS57756B1 (sr) * 2009-11-13 2018-12-31 Astrazeneca Ab Formulacije tableta sa dva sloja
EP2441442A1 (en) 2010-10-08 2012-04-18 LEK Pharmaceuticals d.d. A pharmaceutical composition comprising a thiazolidinedione
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US20120177730A1 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
EP3106165B1 (en) 2011-01-10 2019-02-27 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
NZ626578A (en) 2012-01-06 2016-11-25 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
JP2015503582A (ja) 2012-01-06 2015-02-02 エルセリクス セラピューティクス インコーポレイテッド ビグアナイド組成物および代謝障害を治療する方法
CN108451923B (zh) * 2018-05-31 2025-05-06 常州兰陵制药有限公司 盐酸二甲双胍速释胶囊及其制备方法
US12421245B2 (en) 2020-04-01 2025-09-23 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Pharmaceutically acceptable acid salt of free base of GLP1 receptor agonist, and preparation method therefor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4613596Y1 (pl) * 1969-06-02 1971-05-14
DE2347531A1 (de) * 1973-09-21 1975-04-30 Hoechst Ag Arzneizubereitungen zur oralen diabetes-behandlung
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
JPH0553521A (ja) 1991-08-28 1993-03-05 Mitsubishi Electric Corp オートトラツキング型ｃｒｔデイスプレイモニタ
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US6183778B1 (en) * 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
GB9612496D0 (en) 1996-06-14 1996-08-14 De La Rue Thomas & Co Ltd Security device
PE71699A1 (es) 1997-02-07 1999-08-03 Sepracor Inc Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
EA003144B1 (ru) * 1997-06-18 2003-02-27 Смитклайн Бичам Плс Способ лечения диабета тиазолидиндионом и метформином
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6117451A (en) * 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
SI1131070T1 (sl) 1998-11-12 2008-12-31 Smithkline Beecham Plc Farmacevtski sestavek za modificirano sproĺ äśanje senzibilizatorja za inzulin in metformina
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AR023699A1 (es) 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
GB9824893D0 (en) 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
JP2003514011A (ja) 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
US6461639B2 (en) * 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
US6403121B1 (en) * 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6524621B2 (en) * 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition

Also Published As

Publication number Publication date
BG65616B1 (bg) 2009-03-31
KR20030019300A (ko) 2003-03-06
EP1913945A2 (en) 2008-04-23
BG106747A (en) 2003-01-31
HUP0204122A2 (hu) 2003-03-28
JP4865975B2 (ja) 2012-02-01
HU229960B1 (hu) 2015-03-30
TWI240626B (en) 2005-10-01
AU775654B2 (en) 2004-08-12
SK6792002A3 (en) 2002-09-10
UY26439A1 (es) 2001-07-31
MXPA02005005A (es) 2003-10-14
SI1231918T1 (en) 2005-08-31
CA2388846A1 (en) 2001-05-25
NO20022334L (no) 2002-07-09
HUP0204122A3 (en) 2006-01-30
CZ302500B6 (cs) 2011-06-22
IL149618A0 (en) 2002-12-01
SK286985B6 (sk) 2009-08-06
NO20022334D0 (no) 2002-05-15
EA004878B1 (ru) 2004-08-26
IL190220A0 (en) 2008-11-03
WO2001035941A2 (en) 2001-05-25
NZ518946A (en) 2003-10-31
HK1049788B (en) 2005-11-04
RS51343B (sr) 2011-02-28
WO2001035941A8 (en) 2002-08-29
PE20011011A1 (es) 2001-10-28
IL149618A (en) 2008-07-08
EP1231918B1 (en) 2005-04-06
AP2002002505A0 (en) 2002-06-30
DZ3251A1 (fr) 2001-05-25
BR0015605A (pt) 2002-07-09
JP2003514012A (ja) 2003-04-15
MY125516A (en) 2006-08-30
AR030920A1 (es) 2003-09-03
HRP20020416A2 (en) 2004-08-31
US20070275054A1 (en) 2007-11-29
AR057970A2 (es) 2007-12-26
ME00318B (me) 2011-05-10
AU2008207375A1 (en) 2008-09-11
US8236345B2 (en) 2012-08-07
PL200943B1 (pl) 2009-02-27
UA73150C2 (uk) 2005-06-15
HRP20020416B1 (hr) 2011-04-30
ATE292466T1 (de) 2005-04-15
DE60019329T2 (de) 2006-03-09
NO329926B1 (no) 2011-01-24
EP1913945A3 (en) 2008-04-30
PT1231918E (pt) 2005-08-31
DK1231918T3 (da) 2005-08-01
CN1414852A (zh) 2003-04-30
AU2004226955B2 (en) 2008-08-28
AU2004226955A1 (en) 2004-12-02
AU1404001A (en) 2001-05-30
EP1520581A1 (en) 2005-04-06
OA12513A (en) 2006-05-29
EA200200571A1 (ru) 2002-12-26
CN1222290C (zh) 2005-10-12
DE60019329D1 (de) 2005-05-12
AP1389A (en) 2005-04-14
MA25567A1 (fr) 2002-10-01
KR100760063B1 (ko) 2007-09-18
WO2001035941A3 (en) 2002-05-23
YU38802A (sh) 2005-03-15
ES2240199T3 (es) 2005-10-16
HK1049788A1 (en) 2003-05-30
JP2011252007A (ja) 2011-12-15
EP1231918A2 (en) 2002-08-21
JP5282130B2 (ja) 2013-09-04
CO5300392A1 (es) 2003-07-31
MEP34008A (en) 2011-02-10

Similar Documents

Publication Publication Date Title
PL355331A1 (pl) Nowa kompozycja i zastosowanie
DE69931925D1 (de) 2-chinolonen enthaltende arzneimittel
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
HUP0201103A3 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
HUP0400932A3 (en) Pharmaceutical composition containing nateglinide and another antidiabetic compound, process for its preparation and for use the same
PL375789A1 (pl) Nowe aromatyczne pochodne fluoroglikozydu, środkilecznicze zawierające te związki oraz ich zastosowanie
ZA200203368B (en) Pharmaceutical composition comprising a combination of metformin and glibenclamide.
HUP0303148A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation
RS50485B (sr) Terapeutske kombinacije koje sadrže amplodipin i atorvastatin
EP1405859A4 (en) NITROGENIC HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, MEDICAL USE AND INTERMEDIATE PRODUCTS CONTAINING THEREOF
PL347471A1 (en) Novel n-(iminomethyl)amine derivatives, their preparation, their use as medicines and compositions containing them
WO2001035940A3 (en) Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
HUP0200996A3 (en) Amine derivatives, pharmaceutical compositions containing them and their use
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
WO2002067865A3 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
IL137365A0 (en) Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0200121A3 (en) Calcilytic compounds, pharmaceutical compositions containing them and their use
HUP0300295A3 (en) Substituted benzamide derivatives, pharmaceutical compositions containing them and their use
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
IL162385A (en) Benzothiazole - and benzoxazole - 4,7 - dione derivatives, uses thereof for the preparation of a medicament, medicaments containing them and pharmaceutical compositions containing them
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
GEP20043225B (en) 1-Trifluoromethyl-4-Hydroxy-7- Piperidinyl-Aminomethylchroman Derivatives
EP1234834A4 (en) 1,3,4-OXADIAZOLINE-2-ONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING SUCH DERIVATIVES USEFUL AS ACTIVE INGREDIENT